Exact Sciences Balance Sheet Health
Financial Health criteria checks 4/6
Exact Sciences has a total shareholder equity of $3.1B and total debt of $2.4B, which brings its debt-to-equity ratio to 75.2%. Its total assets and total liabilities are $6.5B and $3.3B respectively.
Key information
75.2%
Debt to equity ratio
US$2.36b
Debt
| Interest coverage ratio | n/a |
| Cash | US$777.64m |
| Equity | US$3.15b |
| Total liabilities | US$3.33b |
| Total assets | US$6.47b |
Recent financial health updates
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Recent updates
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans
Oct 13Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely
Aug 15Exact Sciences GAAP EPS of -$0.94 beats by $0.14, revenue of $521.64M beats by $25.5M
Aug 02Exact Sciences Won't Likely Escape Consolidation In The Industry
May 25Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
May 14Financial Position Analysis
Short Term Liabilities: EXAS's short term assets ($1.2B) exceed its short term liabilities ($514.7M).
Long Term Liabilities: EXAS's short term assets ($1.2B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: EXAS's net debt to equity ratio (50.4%) is considered high.
Reducing Debt: EXAS's debt to equity ratio has reduced from 101.8% to 75.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable EXAS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: EXAS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0% per year.